Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash & Equivalents (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Cash & Equivalents for 4 consecutive years, with $61.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 84.0% to $61.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.3 million through Dec 2025, down 84.0% year-over-year, with the annual reading at $61.3 million for FY2025, 84.0% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $61.3 million at Centessa Pharmaceuticals, up from $50.8 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $544.5 million in Q1 2022, with the low at $44.2 million in Q2 2025.
  • Average Cash & Equivalents over 4 years is $241.1 million, with a median of $158.4 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents skyrocketed 199.32% in 2024, then plummeted 87.14% in 2025.
  • Over 4 years, Cash & Equivalents stood at $393.6 million in 2022, then tumbled by 67.48% to $128.0 million in 2023, then surged by 199.32% to $383.2 million in 2024, then tumbled by 84.0% to $61.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $61.3 million, $50.8 million, and $44.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.